ALDEYRA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ALDEYRA THERAPEUTICS, INC. (ALDX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $13.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-06
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $0.00.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $13.00K, a 96.40% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $0.00.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $83.01K.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $443.73K, a 233.73% increase from fiscal 2024.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $132.96K, a 93.37% decline from fiscal 2023.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $2.01M, a 383.90% increase from fiscal 2022.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $414.68K, a 83.07% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $13.00K 10-Q · filed 2026-08-06 | $13.00K derived: sum of 3 quarters · filed 2026-08-06 | $96.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $13.00K 10-Q · filed 2026-05-07 | $13.00K derived: sum of 2 quarters · filed 2026-05-07 | $96.00K derived: sum of 3 quarters · filed 2026-05-07 | $96.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $83.01K derived: sum of 2 quarters · filed 2026-02-27 | $83.01K derived: sum of 3 quarters · filed 2026-02-27 | $443.73K 10-K · filed 2026-02-27 |
| 2025-09-30 | $83.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $83.01K derived: sum of 2 quarters · filed 2025-11-05 | $443.73K 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $360.73K 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | $360.73K 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $132.96K 10-K · filed 2025-02-28 | |||
| 2023-12-31 | $2.01M 10-K · filed 2024-03-07 | |||
| 2022-12-31 | $414.68K 10-K · filed 2023-03-09 | |||
| 2021-12-31 | $2.45M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |